How do GLP‑1 drugs affect cardiovascular risk markers while on treatment versus after discontinuation?
GLP‑1 receptor agonists improve multiple cardiovascular risk markers—weight, glycaemic control, blood pressure, lipids and inflammatory biomarkers—and reduce major adverse cardiovascular events (MACE)...